Autism and Private Equity: A Cautionary Tale
What does the bankruptcy of CARD, the largest autism treatment company in the U.S., have to teach us about the role of private equity in health care?
Does Applied Behavior Analysis Really Help People with Autism?
The leading U.S. therapy for autism is no panacea and has shown mixed results. Critics say it’s time to look for alternatives—and consult people with autism.
Social Media, AI, and the Battle for Your Brain
Proto.life interviews law professor and ethicist Nita Farahany and techno-humanist Aza Raskin at the BrainMind Summit.
The Urgent Problem of Regulating AI in Medicine
How should medical AI be regulated, and who is responsible when deadly mistakes occur?
Gene Therapies for Eternal Youth
Longevity startups are riding high as a wave of gene therapies advance through clinical trials. Can they actually turn back the clock?
Prenatal Screening for Autism is an Ethical Dilemma
Autism is highly heritable—but is it a disease? Should it be cured? Could screening for it lead to eugenics? We explore the complicated landscape.
School of Shrooms
Oregon’s grand experiment in training psychedelic facilitators is facing a tangle of ambiguity and red tape.
Could Gene-Edited Hens Stop the Great Chicken Massacre?
Researchers have designed a light-activated genetic kill switch to prevent male chicks from hatching, since they have no economic value.
Talking to Trees and Listening to Sheep
A book about shamanic journeys in the backyard and another about the dietary wisdom of roaming herbivores.